After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets
This article was originally published in PharmAsia News
Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.
You may also be interested in...
GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.